FORA Capital LLC Invests $103,000 in Emergent BioSolutions Inc. (NYSE:EBS)

FORA Capital LLC purchased a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 12,290 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Emergent BioSolutions by 14.7% during the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Millennium Management LLC lifted its holdings in Emergent BioSolutions by 5.8% during the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 52,144 shares in the last quarter. American Century Companies Inc. boosted its position in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after buying an additional 623,201 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after buying an additional 316,700 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Emergent BioSolutions by 75.4% in the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after buying an additional 233,341 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EBS has been the topic of several recent research reports. Benchmark raised their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Up 0.1 %

NYSE:EBS opened at $10.12 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The stock’s fifty day simple moving average is $9.10 and its 200-day simple moving average is $8.43. The firm has a market capitalization of $548.34 million, a P/E ratio of -2.47 and a beta of 1.57.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.